AnalystBook Research · Company Intelligence

FONAR CORP

FONRNasdaq

Built from FONAR CORP's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Revenue increased 1.4% to $104.4M, while Net income decreased 21.1% to $8.3M.

The read at a glance✓ Audited against SEC data
  • ScaleFY2025 revenue $104.4MOK
  • ProfitabilityNet income $8.3MOK
  • Cash generationFree cash flow $7.5MOK
  • AccountingDistress score not computed · no manipulation flag · earnings quality not computedNote
  • Insiders0 buys; 0 sells in 365 daysNote
  • CapitalComparable payout data unavailableNote

Business

FONAR CORP: Our physician management and diagnostic services segment is conducted through our subsidiary Health Management Corporation of America ("HMCA").

Where the revenue comes from

Fiscal 2025, as FONAR CORP reports it. History and quarterly detail are in the app.

  • Total$104.4M
  • Managementof Diagnostic Imaging Centers$95.4M
  • Manufacturingand Servicingof Medical Equipment$9.0M

Leadership changes

From FONAR CORP's own filings, the day they're filed.

  • V. Chan · director · departure

Latest filings

  • 8-K · Company announcement2026-06-03
  • 8-K · Company announcement2026-05-29
  • 8-K · Company announcement2026-05-21
  • 8-K · Company announcement2026-05-12
  • 10-Q · Quarterly report2026-05-11
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about FONAR CORP, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.